allogeneic– tag –
-
REPROCELL Enables Clinical-Scale iPSC Manufacturing with StemEdit and Bioreactor Technologies
REPROCELL Japan Overview REPROCELL is facilitating a seamless transition from lab-scale iPSC manufacturing to GMP production and clinical application by integrating its StemEdit gene-editing platform with ABLE Biott and BioThrust bioreac... -
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
Stem Cell Engineering and Automation Propel Allogeneic Cell Therapy Market Towards $1.97 Billion by 2026
GlobeNewswire (via Report Summary) USA Overview A new market study by Open PR forecasts a robust expansion for the allogeneic cell therapy market, projecting it to reach $1.97 billion by 2026. This significant growth is attributed to adv... -
XellSmart’s iPSC Parkinson’s Therapy XS411 Granted FDA Fast Track Designation, Accelerating Commercialization
Longevity.Technology UK Overview XellSmart's XS411, an allogeneic iPSC-derived cell therapy for Parkinson's disease, has received FDA Fast Track designation. This designation aims to expedite the development and review of therapies for s... -
Capricor Therapeutics’ GMP Facility Now Operational to Support Initial Commercial Launch of Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics USA Overview Capricor Therapeutics reported in its Q2 2026 financial results that its San Diego GMP manufacturing facility is operational to support the initial commercial launch of Deramiocel, an allogeneic cardiac... -
Commercial-Scale iPSC Cell Therapy: Advancements in Off-the-Shelf Treatments, Immunogenicity, and Cost Reduction are Key
The Medicine Maker UK Overview This article examines the challenges and technological advances in scaling induced pluripotent stem cell (iPSC) platforms for commercial cell therapies. It highlights the shift towards allogeneic, off-the-s... -
Xellsmart Secures FDA Fast Track Designation for Parkinson’s iPSC-Derived Cell Therapy, Accelerating CNS Pipeline
Longevity.Technology UK Overview Xellsmart announced its allogeneic, off-the-shelf iPSC-derived cell therapy for Parkinson's disease has received FDA Fast Track designation, expected to accelerate its development program. Specializing in... -
Allogene Therapeutics’ TALEN-Edited Lymphoma Cell Therapy cema-cel Receives FDA RMAT and Fast Track Designations, Achieves 58.3% MRD Negativity in Phase 2 Trial
PRISM MarketView USA Overview Allogene Therapeutics' TALEN-edited allogeneic cell therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, accelerating its regulatory pa... -
Rapid Rise of iPSC-Based Therapies: Closed, Automated Cell Culture Systems Address Scalability and Cost Challenges for Allogeneic Treatments
Contract Pharma USA Overview Contract Pharma reported on the rapid advancements in iPSC-derived therapies, highlighting their potential as scalable solutions for allogeneic treatments and complex indications. The article details key chal... -
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif...
